The scientific community and the general public are intrigued by the potential use of gene therapy to tackle disease at its origin, and the resulting benefits to the quality of lif. At the same time, pharmaceutical researchers are beginning to appreciate how an understanding of the genetic basis of disease, and its associated technologies may revolutionize the discovery process for new drugs. Therefore, companies must understand and anticipate how licensing and rights issues are likely to evolve with the science.